
Batoclimab, a novel monoclonal antibody targeting FcRn, shows rapid and significant efficacy in treating Graves’ disease, particularly in patients who haven't responded well to standard antithyroid drugs, by reducing IgG and TRAb levels.


coremsg

A preliminary study showed first evidence of normalization of T3, T4, within weeks, with additional thyroid eye disease effects.

Batoclimab Shows Rapid Effect on Key Graves’ Disease Markers

batoclimab-demonstrates-promising-results-in-phase-2a-trial-for-graves-disease


Batoclimab Demonstrates Promising Results in Phase 2a Trial for Graves’ Disease


title_rewrite


A novel glucose-sensitive insulin conjugate, NNC2215, demonstrates the potential to improve glycemic control and reduce the risk of hypoglycemia in diabetes treatment by adapting its bioactivity to fluctuating glucose levels.


NNC2215 is an insulin conjugate that can reversibly adjust its bioactivity in response to a diabetes-relevant glucose range in vivo.

Glucose-sensitive insulin with attenuation of hypoglycaemia - Nature

glucose-sensitive-insulin-conjugate-nnc2215-shows-promise-in-mitigating-hypoglycemia-risks-in-diabetes-treatment


Glucose-Sensitive Insulin Conjugate (NNC2215) Shows Promise in Mitigating Hypoglycemia Risks in Diabetes Treatment



This research demonstrates a novel approach to continuous health monitoring by developing a minimally invasive, biocompatible microneedle patch capable of extracting interstitial fluid for biomarker analysis.


3d-printed-biocompatible-hollow-microneedle-patch-for-minimally-invasive-interstitial-fluid-extraction


3D-Printed Biocompatible Hollow Microneedle Patch for Minimally Invasive Interstitial Fluid Extraction
